Skip to main content

Advertisement

Log in

Adjuvant chemotherapy in colorectal cancer

  • Published:
Techniques in Coloproctology Aims and scope Submit manuscript

Abstract

Our aim was to study the three-fold response to treatment, survival rates and toxicity.

Materials and methods

We review 76 patients (median age 66.2 years) affected with the disease. All received adjuvant chemotherapy, while 13 with rectal cancer were subjected to radiation too. Patients were staged after Duke’s classification.

Results

Recurrence was noted in 15 patients, 3 at stage B and 12 at stage C; median recurrence-free interval was 18.9 months. Patients without relapse had a median disease-free period of 35.9 months. Median overall survival was 35.21 months. The 5-year survival mark have surpassed 14 patients (3 with recurrent disease): 8 at stage B and 6 at stage C. Ten have died; median survival in these patients was 30.5 months. No patients suffered from severe bone marrow toxicity; mucositis and diarrhoea grade III/IV was noted in 10 patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to I. Delithanasis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Papadopoulou-Zekeridou, P., Alexandridis, E., Delithanasis, I. et al. Adjuvant chemotherapy in colorectal cancer. Tech Coloproctol 8 (Suppl 1), s149–s151 (2004). https://doi.org/10.1007/s10151-004-0140-y

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10151-004-0140-y

Key words

Navigation